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ABSTRACT 
The solution here proposed can be used to conduct economic analysis in randomized clinical trials. 
It is based on a statistical approach and aims at calculating a revised version of the incremental cost-
effective ratio (ICER) in order to take into account the key factors that can influence the choice of 
therapy causing confounding by indication. Let us take as an example a new therapy to treat cancer 
being compared to an existing therapy with effectiveness taken as time to death.  A challenging 
problem is that the ICER is defined in terms of means over the entire treatment groups. It makes no 
provision for stratification by groups of patients with differing risk of death.  For example, for a fair 
and unbiased analysis, one would desire to compare time to death in groups with similar life 
expectancy which would be impacted by factors such as age, gender, disease severity, etc. The 
method we decided to apply is borrowed by cluster analysis and aims at (i) discard any outliers in 
the set under analysis that may arise, (ii) identify groups (i.e. clusters) of patients with "similar" key 
factors. 
INTRODUCTION 
The value of a new drug or therapy is often evaluated in terms of Incremental Cost Effectiveness 
Ratio (ICER) [1]. It is an equation used commonly in health economics to provide a practical 
approach to decision making regarding health interventions, in fact within a trial of two 
interventions it is the measure primarily used to compare the cost-effectiveness of the experimental 
treatment relative to the control treatment. The equation for ICER is: 
 = 	

	, 
where  and  are the mean costs, and  and are the mean effects for the experimental and 
control treatments, respectively. 
In order to take into account characteristic key factors of the therapy (e.g. age, LVEF and NYHA in 
a ICD therapy [2]), we consider the generic set P of n patients each described by m variables (key 
factors) as a data table P(n,m) with n rows and m columns. Our goal can be stated as follows: 
Goal. Identify k subsets (called ) of the set P containing   elements with ∑  ≤ , such that 
each of them contains patients with similar key factors, and such that: ∑  +  =   , with  
the numbers of outliers discarded by the method. The calculation of the index  on the 
elements of each group of patients must lead us to construct the overall incremental cost 
effectiveness ratio (ICER). 
Although we could assume some statistical properties of the distributions involved, in the following 
we will work under the following hypothesis: 
Hypotesis. No assumption about prior distribution or other parametric choices will be considered. 
 
 
 
RELATED WORK 
Methods for describing the distributional properties of ICER statistics have been reported in the 
past,  however, they are challenging even before the notion of stratification is added. In general, the 
distribution of the ratio of two statistics (in this case, the ratio in the difference of two means) is 
complicated. Interesting approaches such as Fieller’s theorem have been suggested.  More 
successful have been approaches base on the bootstrap [3]. However the work of Abadie and 
Imbens [4] suggests more caution should be exercised before approaches based on patient matching 
and stratification are embarked upon.  
 
RATIONALE OF THE METHOD 
An outlier is an observation that, as atypical or erroneous, deviates significantly from the behavior 
of other data, with reference to the type of analysis considered [5, 6, 7]. In our problem there could 
be among the patients a subset with some characteristics (i.e. key factors) very dissimilar to the 
others that could negatively affect the economic analysis in randomized clinical trials.  
The method proposed exploits the theories of cluster analysis, and as a first step it identifies those 
points of the set under analysis that have "distance" from the centroid (in terms of standard 
deviations) more than a specific threshold away. As an example to make clear the idea, in figure 1 is 
depicted the Mahalanobis distance from the centroid of each point in a certain set of data. The 
potential outliers are those more distant from the centroid. The Mahalanobis distance is one of the 
possible distance that can be considered, it has the important characteristic that it takes into account 
the context of the data that is the relation between data. The rational is the same for the more 
common euclidean distance as well. 
 
 
Figure 1 - Distance from each point in  a set to the centroid (the spikes are potential errors in the set) 
 
The cluster analysis applied to the set of patients data identifies a certain number (say 
In each of these group it will be calculated the incremental 
analysis applied may provide a situation similar to that depicted in the Figure 2.
 
The clusters obtained in this way are composed intrinsically of  a homogeneous set of individuals 
and contain both patients belongin
the control treatment group. Thus for each of these clusters it is possible to calculate the index
ICER#, and then calculate the overall ICER in accordance with the formula provided in the 
following (see Step 3).
 
  
Figure 2 - Representation of a typical scenario after the application of cluster analysis to the data of the patients involving in 
 
SOLUTION
Here it is proposed a method based on cluster analysis. In particular we try to automate the 
calculation by means of classification of patients in a set of clusters in order to achieve the goal. 
The method is composed of three sequential steps described i
provided in Figure 3):
 
 
 
 
g to the experimental treatment group and patients belonging to 
clinical trials. 
cost effective ratio. At this point the 
n the following (the diagram is 
k) of groups. 
 
 
 
 
STEP ONE (cluster analysis) 
First of all the data related to the patients are stored in an array P of n rows (total number of the 
patients involved in the clinical trial) and m columns (number of key factors). We assume that from 
a particular attribute of each patient (e.g. the identification code) we can distinguish if he belongs to 
the experimental treatment group or to the control treatment group.  
The algorithm called DBSCAN is applied to the objects in P. It is a data clustering algorithm 
proposed by Martin Ester, Hans-Peter Kriegel, Jörg Sander and Xiaowei Xu in 1996 [8]. It is a 
density-based clustering algorithm because it finds a number of clusters starting from the estimated 
density distribution of corresponding nodes. DBSCAN is one of the most common clustering 
algorithms and also most cited in scientific literature (see appendix for the code provided in the 
Octave software environment [9]). 
After the application of the algorithm, the objects (i.e. the rows of the array) are classified in k 
clusters plus a set of outlier data (cluster labeled '-1') that represents the patients with characteristics 
too different from the others as to suggest that they have been wrongly chosen for the trial (see 
Figure 2). 
  
STEP TWO (calculation of each ICERj) 
Once we got the k groups of patients we can calculate k indexes ICERj distinguishing between the 
individuals belonging to the experimental treatment group and those belonging to the control 
treatment group, as follows: 
 =
 − 
 − 
, % = 1. . ( 
where: 
k are the clusters identified in step 1 
C#)	and	C#- are the mean costs, and E#)	and	E#- are the mean effects for the experimental and control 
treatments, respectively. 
 
STEP THREE (calculation of the overall ICER) 
The final step consists in the calculation of the overall incremental cost effectiveness ratio based on 
a weighted average of contributions from the k ratios obtained in step two. 
 = 	.  


 
where: 
 = |0123425	3	2ℎ4	78298:	;8<=>| +	 |0123425	3	2ℎ4	4?=493@421:	;98<=>| =  +  
A	 + , number of patients in the cluster j 
 number of patients discarded as potential outliers 
 = ∑  +  , number of patients involved in the clinical trial 
In the following diagram is represented the logical flow of the method. 
 
Figure 3 - Logical flow of the proposed solution. 
 
CONCLUSION 
The method proposed takes into account the effect of strata in a population of patients. It uses the 
key factors associated to each patients as inner properties in order to group them and apply the 
computation separately for each homogenous group. No assumption about prior distribution or 
other parametric choices has been considered. The descriptive parameters of the new overall ICER 
can be written as a function of the corresponding descriptive measures of each index ICER#: 
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Therefore the variability of overall ratio can be expressed in terms of variability of the k indexes 
ICER# (see reference [10] for a comparison of four methods of confidence intervals computation for 
the not stratified version of ICER).  
The action of disregarding anomalous data (see step 1 of the process and the notion of outliers) 
introduces a particular robustness in the proposed method. First of all we observe that clustering the 
data as the first step of the method allows analysis of homogeneous group of patients minimizing 
the overall effect of the observational nature of the data (i.e. non-random). We can state that such an 
algorithm is able to create subsets within a patient population that can provide more detailed 
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information about how the patient will respond to a given drug. Furthermore missing data or 
anomalous data can be distinguished and labeled as outliers in the first step of the process, and 
besides if there are some patients with censored data it is very likely that they are grouped in the 
same cluster.  
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